Immunotherapy based on programmed cell death 1/ligand 1 (PD-1/PD-L1) inhibitors prolongs the survival of EGFR wild type NSCLC patients; however, the efficacy and prognosis in EGFR-mutant NSCLC patients are not satisfactory [3,4,5,6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.